UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 24, 2008
Barrier Therapeutics, Inc.
(Exact name of registrant specified in its charter)
| | | | |
| Delaware | | 000-50680 | | 22-3828030 |
(State or other jurisdiction
of incorporation) | | (Commission File Number) | | (I.R.S. Employer
Identification No.) |
600 College Road East, Suite 3200, Princeton, New Jersey 08540
(Address of principal executive offices)
(609) 945-1200
(Registrant’s telephone number, including area code)
Not Applicable
(Former name and former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Section Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)). |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
On March 24, 2008, Barrier Therapeutics, Inc. (the “Company”) announced that it had been granted a second one-year interim patent term extension to United States Patent Number 4,911,932 by the U.S. Patent and Trademark Office. This patent covers the Vusion® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment formulation and methods of treating diaper dermatitis. This action extends the term of this patent to March 27, 2009.
A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits, Pro Forma Financial Information and Exhibits. |
(d) Exhibits.
99.1 – Press release, dated March 24, 2008, entitled “Barrier Therapeutics Granted Second Interim Patent Term Extension for Vusion® Ointment”
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | BARRIER THERAPEUTICS, INC. |
| | | |
| Date: March 25, 2008 | | | | By: | | /s/ Anne M. VanLent |
| | | | Name: | | Anne M. VanLent |
| | | | Title: | | Executive Vice President, Chief Financial Officer and Treasurer |
